Fantasia, K, Lanzinger, S, Rompicherla, S, Grammes, J, O’Malley, G, Mader, J, Golden, L, Kopp, F, Maahs, D, Jehle, P, Ebekozien, O, Holl, R

Continuous glucose monitoring (CGM), insulin pump, and automated insulin delivery (AID) use improve glycemia and quality of life. Device use has increased in recent years. However, rates of device use in older adults are underreported. The aim of this study is to describe sensor, pump, and AID use and glycemic outcomes in adults with type 1 diabetes (T1D) age <u>></u>60 years from the Type 1 Diabetes Exchange Quality Improvement Collaborative (T1DX-QI) and the Diabetes Patients Follow-up (DPV) registry.

We report cross-sectional data of adults ></u> 60 years with T1D seen in 2022 in the T1DX-QI (n=1217) and DPV (n=2042) registries for device use and HbA1c.

Median age was 67.5 years [interquartile range {IQR} 63.4, 72.8] in T1DX-QI and 68.9 [IQR 63.6, 75.7] in DPV. CGM use was similar (50.3%, 47.9%), insulin pump use was approximately 2x higher (40.7% vs 17%), and AID use approximately 3x higher (20.4% vs. 6.4%) in the T1DX-QI as compared to DPV registry (Fig. 1). HbA1c was lower in T1DX-QI (median 7.1% [6.5, 7.8]) than DPV (median 7.4% [6.8, 8.19]).

Device use was lower with increasing age across both registries. Rates of insulin pump and AID use were higher, and median HbA1c was lower, across all age groups among older adults in the T1DX-QI as compared to the DPV registry.

Click here to read the full abstract